Bird Rock Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bird Rock Bio, Inc.
Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.
Deals Shaping The Medical Industry, February 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
Venture Funding Deals, February 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research, Analytical Equipment and Supplies sectors. This month’s column covers deals announced December 2015 through January 2016.
arGEN-X Plans IPO To Progress Pipeline And Attract Fresh Partnerships
Dutch antibody therapeutics developer arGEN-X BV will use proceeds from a planned summer IPO to progress three clinical assets and further develop its strategy targeting orphan indications, while adding to its growing list of big pharma partners in major indications.
- Drug Delivery
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Anaphore, RuiYi, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.